Anti-tumor immunity induced by tumor cells express a membrane-bound form of IL-2 and SDF-1

Animal Cells and Systems

Volumn 12, Issue 4, 2008, Pages 193-201

  Choi, Jin Wha ^a   Lim, Ho Yong ^a   Chang, Mi Ra ^a   Cheon, Ji Yeon ^a   Kim, Young Sang ^a  

^a Chungnam National University   (South Korea)

Author keywords

Membrane bound form of IL 2; SDF 1; Systemic anti tumor immunity; Tumorigenicity

Indexed keywords

ANIMALIA; MUS;

EID: 77955630278     PISSN: 19768354     EISSN: 21512485     Source Type: Journal    
DOI: 10.1080/19768354.2008.9647173     Document Type: Article

References (55)

1. Allione, A, Consalvo, M, Nanni, P, Lollini, PL, Cavallo, F., Giovarelli, M, Forni, M, Gulino, A, Colombo, MP, Dellabona, P. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res, 54:6022–6026.
2. Armstrong, CA, Botella, R, Galloway, TH, Murray, N, Kramp, JM, Song, IS, and Ansel, JC. 1996. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res, 56:2191–2198.
3. Assenmacher, M, Scheffold, A, Schmitz, J, Segura Checa, JA, Miltenyi, S, and Radbruch, A. 1996. Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. Eur J Immunol, 26:263–267.
4. Atkins, MB, Lotze, MT, Dutcher, JP, Fisher, RI, Weiss, G, Margolin, K, Abrams, J, Sznol, M, Parkinson, D, Hawkins, M. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma:analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 17:2105–2116.
5. Baskar, S, Nabavi, N, Glimcher, LH, and Ostrand-Rosenberg, S. 1993. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother, 14:209–215.
6. Blankenstein, T, Rowley, DA, and Schreiber, H. 1991. Cytokines and cancer:experimental systems. Curr Opin Immunol, 3:694–698.
7. Browning, JL, Ngam-ek, A, Lawton, P, DeMarinis, J, Tizard, R, Chow, EP, Hession, C, O'Brine-Greco, B, Foley, SF, and Ware, CF. 1993. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell, 72:847–856.
8. Campbell, JJ, and Butcher, EC. 2000. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol, 12:336–341.
9. Chang, MR, Lee, WH, Choi, JW, Park, SO, Paik, SG, and Kim, YS. 2005. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Exp Mol Med, 37:240–249.
10. Chen, K, Braun, S, Lyman, S, Fan, Y, Traycoff, CM, Wiebke, EA, Gaddy, J, Sledge, G, Broxmeyer, HE, and Cornetta, K. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res, 57:3511–3516.
11. Cimino, AM, Palaniswami, P, Kim, AC, and Selvaraj, P. 2004. Cancer vaccine development:protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol Res, 29:231–240.
12. Colombo, MP, Modesti, A, Parmiani, G, and Forni, G. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res, 52:4853–4857.
13. Dilloo, D, Bacon, K, Holden, W, Zhong, W, Burdach, S, Zlotnik, A, and Brenner, M. 1996. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med, 2:1090–1095.
14. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K, Jackson, V, Hamada, H, Pardoll, D, and Mulligan, RC. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA, 90:3539–3543.
15. Dunussi-Joannopoulos, K, Zuberek, K, Runyon, K, Hawley, RG, Wong, A, Erickson, J, Herrmann, S, and Leonard, JP. 2002. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1):local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood, 100:1551–1558.
16. el-Shami, KM, Tzehoval, E, Vadai, E, Feldman, M, and Eisenbach, L. 1999. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J Interferon Cytokine Res, 19:1391–1401.
17. Emoto, M, Mittrucker, HW, Schmits, R, Mak, TW, and Kaufmann, SH. 1999. Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+NKT cells. J Immunol, 162:5094–5098.
18. Fearon, ER, Pardoll, DM, Itaya, T, Golumbek, P, Levitsky, HI, Simons, JW, Karasuyama, H, Vogelstein, B, and Frost, P. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60:397–403.
19. Gabrilovich, DI, Ciernik, IF, and Carbone, DP. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol, 170:101–110.
20. Gansbacher, B, Zier, K, Daniels, B, Cronin, K, Bannerji, R, and Gilboa, E. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med, 172:1217–1224.
21. Hillman, GG, Slos, P, Wang, Y, Wright, JL, Layer, A, De Meyer, M, Yudelev, M, Che, M, and Forman, JD. 2004. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther, 11:61–72.
22. Huang, AY, Golumbek, P, Ahmadzadeh, M, Jaffee, E, Pardoll, D, and Levitsky, H. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264:961–965.
23. Jackaman, C, Bundell, CS, Kinnear, BF, Smith, AM, Filion, P, van Hagen, D, Robinson, BW, and Nelson, DJ. 2003. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:a novel mechanism for IL-2. J Immunol, 171:5051–5063.
24. Kim, YS, Sonn, CH, Paik, SG, and Bothwell, AL. 2000. Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity. Gene Ther, 7:837–843.
25. Kimura, K, Nishimura, H, Hirose, K, Matsuguchi, T, Nimura, Y, and Yoshikai, Y. 1999. Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency. Eur J Immunol, 29:1532–1542.
26. Kriegler, M, Perez, C, DeFay, K, Albert, I, and Lu, SD. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein:ramifications for the complex physiology of TNF. Cell, 53:45–53.
27. Kumar, A, Humphreys, TD, Kremer, KN, Bramati, PS, Bradfield, L, Edgar, CE, and Hedin, KE. 2006. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity, 25:213–224.
28. Kundig, TM, Bachmann, MF, DiPaolo, C, Simard, JJ, Battegay, M, Lother, H, Gessner, A, Kuhlcke, K, Ohashi, PS, Hengartner, H. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science, 268:1343–1347.
29. Kurt-Jones, EA, Fiers, W, and Pober, JS. 1987. Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts. J Immunol, 139:2317–2324.
30. Leonard, JP, Sherman, ML, Fisher, GL, Buchanan, LJ, Larsen, G, Atkins, MB, Sosman, JA, Dutcher, JP, Vogelzang, NJ, and Ryan, JL. 1997. Effects of single-dose interleukin-12 exposure on interleukin- 12-associated toxicity and interferon-gamma production. Blood, 90:2541–2548.
31. Lollini, PL, and Forni, G. 2003. Cancer immunoprevention:tracking down persistent tumor antigens. Trends Immunol, 24:62–66.
32. Lu, X, Kallinteris, NL, Li, J, Wu, S, Li, Y, Jiang, Z, Hillman, GG, Gulfo, JV, Humphreys, RE, and Xu, M. 2003. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother, 52:592–598.
33. Luo, L, Chapoval, AI, Flies, DB, Zhu, G, Hirano, F, Wang, S, Lau, JS, Dong, H, Tamada, K, Flies, AS. 2004. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol, 173:5445–5450.
34. Marr, RA, Addison, CL, Snider, D, Muller, WJ, Gauldie, J, and Graham, FL. 1997. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther, 4:1181–1188.
35. Mizoguchi, H, O'Shea, JJ, Longo, DL, Loeffler, CM, Mc Vicar, DW, and Ochoa, AC. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science, 258:1795–1798.
36. Mohle, R, Bautz, F, Denzlinger, C, and Kanz, L. 2001. Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors. Ann N YAcad Sci, 938:26–34. 34–25. discussion
37. Nanki, T, Hayashida, K, El-Gabalawy, HS, Suson, S, Shi, K, Girschick, HJ, Yavuz, S, and Lipsky, PE. 2000. Stromal cell-derived factor- 1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol, 165:6590–6598.
38. Nanki, T, and Lipsky, PE. 2000. Cutting edge:stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol, 164:5010–5014.
39. Nanni, P, Forni, G, and Lollini, PL. 1999. Cytokine gene therapy:hopes and pitfalls. Ann Oncol, 10:261–266.
40. Nizard, P, Gross, DA, Babon, A, Chenal, A, Beaumelle, B, Kosmatopoulos, K, and Gillet, D. 2003. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. J Immunother, 26:63–71.
41. Nomura, T, Hasegawa, H, Kohno, M, Sasaki, M, and Fujita, S. 2001. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1 alpha chemokine genes. IntJ Cancer, 91:597–606.
42. Peled, A, Petit, I, Kollet, O, Magid, M, Ponomaryov, T, Byk, T, Nagler, A, Ben-Hur, H, Many, A, Shultz, L. 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science, 283:845–848.
43. Rivoltini, L, Gambacorti-Passerini, C, Squadrelli-Saraceno, M, Grosso, MI, Cantu, G, Molinari, R, Orazi, A, and Parmiani, G. 1990. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res, 50:5551–5557.
44. Salvadori, S, Gansbacher, B, Pizzimenti, AM, and Zier, KS. 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J Immunol, 153:5176–5182.
45. Shi, M, Hao, S, Su, L, Zhang, X, Yuan, J, Guo, X, Zheng, C, and Xiang, J. 2005. Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses. Cancer Biother Radiopharm, 20:401–409.
46. Sonn, CH, Hee Ryung, Yoon, In Ock, Seong, Mi-Ra, Chang, Yong Chan, Kim, Han-Chul, Kang, Seok-Cheol, Suh, and Young Sang, Kim. 2006. MethA Fibrosarcoma Cells Expressing Membrane-Bound Forms of IL-2 Enhance Antitumor Immunity. J Microbiol Biotech, 16:1919–1927.
47. Soo Hoo, W, Lundeen, KA, Kohrumel, JR, Pham, NL, Brostoff, SW, Bartholomew, RM, and Carlo, DJ. 1999. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J Immunol, 162:7343–7349.
48. Tepper, RI, and Mule, JJ. 1994. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther, 5:153–164.
49. Tepper, RI, Pattengale, PK, and Leder, P. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57:503–512.
50. Tjuvajev, J, Gansbacher, B, Desai, R, Beattie, B, Kaplitt, M, Matei, C, Koutcher, J, Gilboa, E, and Blasberg, R. 1995. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res, 55:1902–1910.
51. Townsend, SE, and Allison, JP. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 259:368–370.
52. Vianello, F, Papeta, N, Chen, T, Kraft, P, White, N, Hart, WK, Kircher, MF, Swart, E, Rhee, S, Palu, G. 2006. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor- 1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol, 176:2902–2914.
53. Yei, S, Bartholomew, RM, Pezzoli, P, Gutierrez, A, Gouveia, E, Bassett, D, Soo Hoo, W, and Carlo, DJ. 2002. Novel membrane-bound GM-CSF vaccines for the treatment of cancer:generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther, 9:1302–1311.
54. Zhang, T, Somasundaram, R, Berencsi, K, Caputo, L, Gimotty, P, Rani, P, Guerry, D, Swoboda, R, and Herlyn, D. 2006. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol, 36:457–467.
55. Zier, K, Gansbacher, B, and Salvadori, S. 1996. Preventing abnormalities in signal transduction of T cells in cancer:the promise of cytokine gene therapy. Immunol Today, 17:39–45.